-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial

PUBT·08/25/2026 11:13:52
Listen to the news
CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial
  • CSPC won FDA clearance to start US clinical trials of its recombinant RSV vaccine candidate SYS 6057.
  • China’s NMPA cleared the same candidate for clinical testing on July 30, 2026.
  • The initial indication targets prevention of RSV-related lower respiratory tract disease in adults aged 60 and older.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298427), on August 25, 2026, and is solely responsible for the information contained therein.